A new study in Molecular Cell identifies a previously undescribed way that loss of the tumor-suppressor gene p53 sets cancer in motion, tracing a direct line from excess RNA production to a shortage of the raw materials cells need to copy their DNA accurately. The work, led by researchers at the Hebrew University of Jerusalem and the German Cancer Research Center (DKFZ) in Heidelberg, Germany, was built on cells from patients with Li-Fraumeni syndrome, a rare inherited condition that carries an unusually high lifetime cancer risk [1].
Key Takeaways
- Loss of p53 causes cells to overproduce RNA, a phenomenon called hypertranscription, thereby depleting the nucleotide pool required for DNA replication [1].
- The resulting nucleotide shortage triggers replication stress, telomere dysfunction, micronuclei formation, and, in severe cases, chromothripsis, a catastrophic shattering and reassembly of a chromosome [1].
- Supplementing cells with nucleosides or reducing transcriptional activity reversed DNA damage in laboratory experiments, though the findings do not yet constitute a treatment strategy [1].
A Second Job for the ‘Guardian of the Genome‘
p53 has long been described as the guardian of the genome because of its established role in the DNA damage response: when DNA is damaged, p53 can halt cell division, allow time for repair, or push a severely damaged cell toward death [1]. This new work describes a distinct and previously unrecognized function. According to the study, p53 also helps maintain RNA production and the supply of DNA building blocks in balance, and when that balance is lost, genome stability suffers even without an external source of DNA damage [1].
RNA and DNA are both built from nucleotides, and transcription is, in ordinary circumstances, one of the largest consumers of the cell’s nucleotide supply [1]. The research team found that when p53 function is lost, cells shift into a state of hypertranscription, producing substantially more RNA than normal. That surge draws down the pool of nucleotides available for a competing and equally essential process, DNA replication, leaving too few building blocks to copy the genome accurately [1][2][3]
From Nucleotide Shortage to Chromosome Shattering
The consequences of that shortage, as described in the study, unfold in a defined sequence. Insufficient nucleotides slow DNA replication and place cells under a state the authors call replication stress, which in turn produces DNA breaks, dysfunction at the protective ends of chromosomes known as telomeres, and micronuclei, small membrane-bound structures that form when fragments of damaged or misplaced DNA are left outside the main nucleus during cell division [1][3][4]. In the most severe cases, this cascade of events can culminate in chromothripsis, a single catastrophic episode in which a chromosome is shattered into numerous pieces and reassembled in the wrong order, generating the kind of large-scale genomic rearrangement that is a recognized feature of many human cancers and has been linked in prior research to tumor development.[1]
To trace this sequence, the investigators followed skin-derived fibroblasts from patients with Li-Fraumeni syndrome, who carry an inherited alteration in one copy of the TP53 gene, over an extended period in culture. This longitudinal approach allowed the team to observe the early molecular changes that accompany progressive p53 loss and to directly link them to the emergence of genomic instability [1]. To test whether the mechanism was specific to this inherited condition or reflected a broader biological principle, the researchers also examined other human cell types, including breast epithelial cells engineered to lack p53, and found the same underlying pattern of hypertranscription and nucleotide depletion [1]. A separate analysis of thousands of tumor samples spanning 31 cancer types, drawn from existing genomic databases, showed that tumors with damaged or absent p53 tended to display unusually elevated RNA output compared with tumors in which p53 remained intact, a pattern consistent with the laboratory findings. [1][3][4][5]
Reversing the Damage in the Laboratory
The study’s authors went on to test whether the sequence they had described could be interrupted. Supplying cells lacking p53 with exogenous nucleosides, the precursor molecules used to build nucleotides, restored the nucleotide pool and reduced both replication stress and DNA damage in these experiments [1]. A separate intervention that lowered the cells’ excessive rate of transcription directly produced a comparable protective effect, reinforcing that hypertranscription itself, rather than some unrelated consequence of p53 loss, was driving the instability. [1][2][5]
What This Does and Does Not Mean for Cancer Care
The authors make it explicit that these findings do not constitute a new cancer treatment, and no clinical application is proposed or implied in the study [1]. What the work does offer is a newly defined molecular mechanism linking one of the most commonly altered genes in human cancer to the specific chromosomal catastrophes long observed in tumors lacking functional p53. The authors suggest that the way cancer cells balance transcription and nucleotide biosynthesis may be a promising direction for future research, though such work remains in its early, exploratory stages. [1][5]
References
[1] Zaatra W, Philippos G, Smirnov P, Milo S, Otoničar J, Chan M, Harel M, Devens F, Goldberg T, Eliassaf A, Grimes K, Irony-Tur Sinai M, Sigismondo G, Laue K, Ben-David U, Geiger T, Korbel JO, Krijgsveld J, Shalev O, Kerem B, Ernst A. Hypertranscription caused by p53 deficiency triggers nucleotide insufficiency that induces replication stress and genomic instability. Mol Cell. 2026 Sep 3;86(17):3411-3430.e14. doi: 10.1016/j.molcel.2026.08.003. PMID: 42691990.
[2] Cortés-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS; PCAWG Structural Variation Working Group; Park PJ; PCAWG Consortium. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2020 Mar;52(3):331-341. doi: 10.1038/s41588-019-0576-7. Epub 2020 Feb 5. Erratum in: Nat Genet. 2023 May;55(5):893. doi: 10.1038/s41588-020-0634-1. Erratum in: Nat Genet. 2023 Jun;55(6):1076. doi: 10.1038/s41588-023-01315-z. PMID: 32025003; PMCID: PMC7058534.
[3] Zatzman M, Fuligni F, Ripsman R, Suwal T, Comitani F, Edward LM, Denroche R, Jang GH, Notta F, Gallinger S, Selvanathan SP, Toretsky JA, Hellmann MD, Tabori U, Huang A, Shlien A. Widespread hypertranscription in aggressive human cancers. Sci Adv. 2022 Nov 25;8(47):eabn0238. doi: 10.1126/sciadv.abn0238. Epub 2022 Nov 23. PMID: 36417526; PMCID: PMC9683723.
[4]Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, Futreal PA, Campbell PJ. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011 Jan 7;144(1):27-40. doi: 10.1016/j.cell.2010.11.055. PMID: 21215367; PMCID: PMC3065307.
[5] Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rücker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012 Jan 20;148(1-2):59-71. doi: 10.1016/j.cell.2011.12.013. PMID: 22265402; PMCID: PMC3332216.
This article is intended for informational purposes for healthcare and life-sciences professionals and does not constitute medical advice. The findings described here are preclinical and laboratory-based; they do not represent a diagnostic tool or treatment recommendation for any cancer type.
Featured image:© 2019 – 2026 Courtesy Hebrew University. Used with permission.
DOI
